Literature DB >> 31416506

[Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms].

Yi-Ling Liu1, Xian-Min Wang, Ting-Ting Chen, Kun Shi, Ya-Heng Lu, Yong-Hong Guo, Yan Li.   

Abstract

OBJECTIVE: To study the clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease (KD) complicated by coronary artery aneurysm (CAA).
METHODS: A total of 77 KD children who were diagnosed with multiple small/medium-sized CAAs by echocardiography between January 2013 and June 2018 were enrolled. They were randomly divided into observation group with 38 children (treated with clopidogrel and aspirin) and control group with 39 children (treated with low-molecular-weight heparin and aspirin). All children were followed up regularly, and the first 3 months of the course of the disease was the observation period. The children were observed in terms of the change of the coronary artery and the incidence of complications.
RESULTS: At month 3 of follow-up, among the children in the observation group, 6 had normal coronary artery, 11 had coronary artery retraction, 19 had stable coronary artery, and 2 progressed to giant coronary aneurysm; among the children in the control group, 7 had normal coronary artery, 12 had coronary artery retraction, 19 had stable coronary artery, and 1 progressed to giant coronary aneurysm; there was no significant difference in the change of the coronary artery between the two groups (P>0.05). There were 2 cases of epistaxis and 6 cases of skin ecchymosis in the observation group, and 1 case of epistaxis and 7 cases of petechiae and ecchymosis at the injection site in the control group, and no other serious bleeding events were observed in either group.
CONCLUSIONS: Clopidogrel combined with low-dose aspirin is safe and effective in antithrombotic therapy for children with KD complicated by CAA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31416506      PMCID: PMC7389908     

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  13 in total

1.  Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)--digest version.

Authors: 
Journal:  Circ J       Date:  2010-08-18       Impact factor: 2.993

2.  Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease.

Authors: 
Journal:  Pediatr Int       Date:  2005-12       Impact factor: 1.524

3.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  Kawasaki disease: insights into pathogenesis and approaches to treatment.

Authors:  Stanford T Shulman; Anne H Rowley
Journal:  Nat Rev Rheumatol       Date:  2015-04-28       Impact factor: 20.543

5.  2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Authors:  Stephan Windecker; Philippe Kolh; Fernando Alfonso; Jean-Philippe Collet; Jochen Cremer; Volkmar Falk; Gerasimos Filippatos; Christian Hamm; Stuart J Head; Peter Jüni; A Pieter Kappetein; Adnan Kastrati; Juhani Knuuti; Ulf Landmesser; Günther Laufer; Franz-Josef Neumann; Dimitrios J Richter; Patrick Schauerte; Miguel Sousa Uva; Giulio G Stefanini; David Paul Taggart; Lucia Torracca; Marco Valgimigli; William Wijns; Adam Witkowski
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

6.  Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013).

Authors: 
Journal:  Circ J       Date:  2014-09-30       Impact factor: 2.993

7.  Image-based modeling of hemodynamics in coronary artery aneurysms caused by Kawasaki disease.

Authors:  Dibyendu Sengupta; Andrew M Kahn; Jane C Burns; Sethuraman Sankaran; Shawn C Shadden; Alison L Marsden
Journal:  Biomech Model Mechanobiol       Date:  2011-11-27

Review 8.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.

Authors:  Brian W McCrindle; Anne H Rowley; Jane W Newburger; Jane C Burns; Anne F Bolger; Michael Gewitz; Annette L Baker; Mary Anne Jackson; Masato Takahashi; Pinak B Shah; Tohru Kobayashi; Mei-Hwan Wu; Tsutomu T Saji; Elfriede Pahl
Journal:  Circulation       Date:  2017-03-29       Impact factor: 29.690

9.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

Review 10.  Recent Advances in Kawasaki Disease.

Authors:  Kyu Yeun Kim; Dong Soo Kim
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

View more
  1 in total

1.  [Pediatric expert consensus on the application of aspirin in Kawasaki disease].

Authors: 
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.